Trial Profile
Evaluation of Panobinostat (LBH589) as Maintenance Therapy in Multiple Myeloma Following Autologous Hematopoietic Cell Transplantation
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 03 Nov 2022
Price :
$35
*
At a glance
- Drugs Panobinostat (Primary)
- Indications Multiple myeloma
- Focus Therapeutic Use
- 28 Oct 2022 Status changed from active, no longer recruiting to completed.
- 13 May 2022 Planned End Date changed from 1 Jun 2022 to 1 Dec 2022.
- 09 Apr 2020 Planned End Date changed from 1 Jun 2021 to 1 Jun 2022.